Model-Based Dosing of Anti-Thymocyte Globulin in Pediatric Allogeneic Hematopoietic Cell Transplantation Improves Survival Chances: Updated Results from the Single Arm Phase II Parachute-Trial Combined with Real-World Data

Anti-thymocyte globulin (ATG) is used in the conditioning for pediatric hematopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure (GF). Toxicity includes poor T-cell recovery, associated with viral reactivations and higher mortality. The PARACHUTE-trial1 (non-randomized prospective trial investigating model-based dosing [MBD] compared to historical fixed dose of ATG Thymoglobulin) showed that MBD of ATG improves T-cell recovery compared to fixed dosing, while maintaining an anti-GvHD effect.

https://www.astctjournal.org/article/S2666-6367(23)01882-1/fulltext?rss=yes

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Rick Admiraal, Stefan Nierkens, Marc Bierings, Mirjam Belderbos, Alwin D.R. Huitema, Robbert Bredius, Yilin Jiang, Kevin J. Curran, Andrew C. Harris, Andromachi Scaradavou, Maria I. Cancio, Elizabeth Klein, Wouter Kollen, Dorine Bresters, Friso Calkoen, A Tags: 109 Source Type: research